Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Entrada Therapeutics (TRDA) Accumulated Depreciation & Amortization (2022 - 2025)

Entrada Therapeutics has reported Accumulated Depreciation & Amortization over the past 4 years, most recently at $9.9 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $9.9 million for Q4 2025, up 5.41% from a year ago — trailing twelve months through Dec 2025 was $9.9 million (up 5.41% YoY), and the annual figure for FY2025 was $9.9 million, up 5.41%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $9.9 million at Entrada Therapeutics, down from $10.2 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for TRDA hit a ceiling of $11.3 million in Q2 2025 and a floor of $1.8 million in Q1 2022.
  • Median Accumulated Depreciation & Amortization over the past 4 years was $6.3 million (2023), compared with a mean of $6.5 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 112.62% in 2023 and later increased 5.41% in 2025.
  • Entrada Therapeutics' Accumulated Depreciation & Amortization stood at $3.3 million in 2022, then surged by 79.43% to $5.9 million in 2023, then skyrocketed by 59.11% to $9.4 million in 2024, then increased by 5.41% to $9.9 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $9.9 million (Q4 2025), $10.2 million (Q3 2025), and $11.3 million (Q2 2025) per Business Quant data.